Earli, which raised $105M in two rounds, is developing 'Cancer-Activated Promoters' that are set off by cancer-specific transcription factors and turn tumor cells into therapeutic payload factories
Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months
Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data
Barclays Miami: Barclays' Head of Healthcare M&A shares his take on the current environment of dealmaking



BiotechTV - News